Skip to main content
Oregon.gov Homepage

Pharmacy and Therapeutics Committee



Ensuring Safe, Effective and Affordable Medications for Oregonians

The Pharmacy and Therapeutics (P&T) Committee is an 11-member advisory committee of physicians, pharmacists and consumer representatives. The Committee performs drug use reviews and advises the Oregon Health Authority (OHA) on which prescription drugs should be included on any preferred drug list (PDL) established by OHA.

OHA contracts with Drug Use Research and Management (DURM) to administer and lead P&T meetings. DURM is a project of Oregon State University's College of Pharmacy. Complete meeting agendas, meeting packets, written testimony, and OHA recommendations are available on the DURM Meetings Page.

Public Engagement & Testimony

OHA values public input. P&T Committee meetings are open to the public* and there is opportunity for public testimony at each meeting.

Please see the P&T Operating Procedures for information on how you may provide public comment, Committee processes, including information on how the DURM group assesses quality and grades evidence.

Anyone providing public testimony (either in person or in writing) will be required to complete a Public Comment/Testimony Declaration form to disclose all conflicts of interest. Completed forms must be submitted with written testimony before the meeting and must be submitted at the meeting for in-person testimony. Email completed forms to DURM at OSUPharm.DI@oregonstate.edu.

Seeking Committee Members

OHA continuously accepts applications for the P&T Committee. To apply, complete the Committee Application email to OHA.Pharmacy@dhsoha.state.or.us.

 

*As required by ORS 414.356, the Committee meets in executive session for limited purposes such as reviewing confidential drug pricing information and discussing profiles of individual patients.

Upcoming Meetings

Next Meeting

P&T Committee

Useful Links

*Note: Contact CCOs for their PA Criteria and preferred drug lists.

Questions?

Contact: Pharmacy Program

Subscribe to receive email updates.